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During the past decade many new molecular methods for DNA and RNA analysis have emerged. The most popular
thus far have been SSCP, HET, CMC, DGGE, RFLP or ASA, which have now been replaced by methods that are more
cost effective and less time consuming. Real-time amplification techniques and particularly those with the capacity
of multiplexing have become commonly used in laboratory practice. Novel screening methods enable the very
rapid examination of large patients series. Use of liquid handling robotics applied to the isolation of DNA or RNA,
the normalisation of sample concentration, and standardization of target amplification by PCR have also
contributed to a reduced risk of sample contamination and have resulted in laboratory analysis being easier and
faster.
The aim of this study is the introduction of a few modern techniques, most commonly used in detection of genetic
predisposition to cancer.
Keywords: Constitutional changes, Hereditary cancer, Techniques, DiagnosesSeveral genes have been identified which, if mutated, are
associated with increased predisposition to cancer [1].
Persons harbouring mutations in these genes have an
altered risk of cancer from a few percent to as much as
90% compared to the non-affected controls. A series of
genes associated with an inherited predisposition to can-
cer and those most frequently examined in clinical prac-
tice are summarised in Table 1.
Several molecular methods have been developed that
are specifically designed for detecting mutations that can
be further subdivided into methods aimed at detecting:
 new mutations
 known mutationsDetection of new mutations
The diagnosis of mutations in appropriately selected
cases using pedigree and clinical data is justified in clin-
ical practice, even though mutation detection techniques
can be complex, time-consuming and expensive.* Correspondence: gkurz@sci.pum.edu.pl
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The principal requirements for mutation analysis
include:
 DNA isolation,
 amplification of gene fragments, usually comprising
only coding sequences (but this is beginning to
encompass the promoter regions of genes)
 preliminary detection of changes within
amplification products using screening techniques
 Southern analysis and multiplex ligation-dependent
probe amplification
 high resolution melting analysis
 sequencing and pyrosequencingDNA isolation
Constitutional DNA is usually isolated from whole blood
and less frequently from other tissues. Analysis of con-
stitutional DNA allows the detection of mutations that
occur in all nucleated cells of patients. Optimal DNA
isolation is especially effective if the sample for analysis
is collected within 48 hours of manipulation. Good
results, however, can be achieved even after a few days
of blood storage at room temperature or even as muchral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Genes associated with predisposition to cancer family syndromes. The table contains genes studied the most
frequently in our centre
GENE LOCALISATION PREDISPOSITION TO MALIGNANCIES PENETRANCE*
Rb1 [2] 13q14 retinoblastoma up to 90%
BRCA1 [3] 17q21 breast cancer up to 80%
BRCA2 [3] 13q13 ovarian cancer
prostate cancer
colon cancer




MSH2 [5] 2p21 colon cancer up to 90%
MLH1 [5] 3p22 endometrial cancer for male
MSH6 [5] 2p16 cancer of the stomach, up to 70%
cancer of the biliary tract for female [6]
small bowel cancer
ovarian cancer
*probability of malignancy during lifetime among mutation carriers.
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below zero. If fresh tissue is not available, DNA isolation
can be performed from formalin fixed paraffin embed-
ded tissue blocks, although attaining unequivocal results
using such material is more difficult and sometimes even
impossible. DNA isolation requires elimination of pro-
teins from cellular lysates. Using the phenol-chloroform
method this is achieved by digestion with proteinase K
and extraction in a mixture of phenol and chloroform.
Finally, nucleic acids are extracted using ethyl- or
isopropyl- alcohols. This technique is used, however,
only occasionally even though it produces exceptionally
clean and non-degraded DNA (in practice it is now used
mainly for DNA isolation from paraffin blocks). Other
techniques have been developed that are less laborious
and easier to automatate. They are primarily based on
binding DNA to a synthetic bead that can be easily sepa-
rated from other cellular components (e.g. with dyne
beads) and washed in order to separate out clean and
amplifiable DNA.
Amplification of gene fragments
Targeted DNA fragments are amplified using the poly-
merase chain reaction. The reaction mixture includes:
DNA template (usually genomic DNA), DNA polymer-
ase, a pair of specific primers for the gene segment to be
analysed, deoxyribonucleotide triphosphates and a reac-
tion buffer. This mixture is exposed to cyclic changes of
temperature which activate a heat sensitive DNA poly-
merase that generates a new complementary strand of
DNA from a single strand template. Each cycle includes:
denaturation, annealing initiation and DNA synthesis.After 22 cycles, assuming 100% efficiency, the copy
number of the amplified fragment is increased one mil-
lion-fold.
Preliminary detection of changes within amplification
products using screening techniques
Most screening techniques take advantage of the unique
nature of double stranded DNA. At temperature suffi-
cient to “melt” DNA from a double strand to a single
strand re-annealing can occur. In the presence of a mis-
match the annealing temperature decreases and the
double strand molecule falls apart much more easily
than when there is a perfect match. DNA-SSCP (single
strand conformational polymorphism) was one of the
first methods to take advantage of differences in anneal-
ing temperature and was the most popular technique for
the detection of differences in amplification products
[7]. Other techniques using this principle include HET
(heteroduplex analyses) [8], CMC (chemical mismatch
cleavage) [9], DHPLC (denaturing high-performance
liquid chromatography) [10] and DGGE (denaturing
gradient gel electrophoresis) [11].
DHPLC (denaturing high-performance liquid
chromatography)
At present, the best and the most frequently applied
DNA screening technique for the initial detection of
changes is DHPLC [10,12-15]. This is based on the same
principals as HET but includes high-resolution DNA
specific chromatography columns that under appropriate
conditions can separate DNA sequences differing by as
little as one base. The melting conditions are a function
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take some time to optimize. Amplified DNA fragments
are separated in a gradient of denaturing agent. (The key
to DHPLC is the solid phase, which has differential
affinity for single and double-stranded DNA). Under
sub-denaturing conditions, heteroduplexes have a lower
affinity than homoduplexes to the solid phase of the
column and it is easier to elute them. Separation is mon-
itored by UV absorption measured at 260 nm. The elu-
tion profile (Figure 1) is characteristic and reproducible
for a given change and allows differentiation between
new changes and known mutations or polymorphisms.
Based on reported data [16] and our own experiences
[17] we can state that DHPLC combines the advantages
of several methods. Its sensitivity approaches 100%
[10,14,15]. At the same time the cost is relatively low
(reagent costs per sample ~ 5–10 Euro). The method is
rapid, and if an auto-sampler is used, it can allow up to
200 samples per day to be analysed.
DNA sequencing
Sequencing is considered to be the most sensitive tech-
nique for the detection of changes in genomic material,
allowing at the same time their full characterisation and
it is often considered to be the “Gold Standard” of muta-
tion detection.
Since the 1990’s, significant progress in DNA sequen-
cing technologies has been achieved by the introduction
of automated DNA fragment analysers, for which the
identification of particular nucleotides is based on base
specific fluorescent dyes that are activated by laser emis-
sion. Each nucleotide (A, C, G, T) is labelled with a differ-
ent fluorescent dye, which is detected by a laser targeting
the excitation wavelength of the fluorescent dye and the
resultant emission identified by a photomultiplier.Figure 1 DHPLC elution profile characteristic for c.1786_1788delAAT
to ‘wild’ type (dashed line).The most convenient sequencing assay relies on a
cyclic sequencing [18] based on the classical Sanger
method. During the analysis the PCR amplified
sequences of the target products of both the forward
and reverse DNA strands are assessed. Any legitimate
change is detected in both DNA strands. The sequen-
cing procedure comprises several stages that include:
 preparative PCR – amplification of the target
fragment of the gene using specific primers pairs,
 asymmetric PCR – separate amplification with each
of the primers using a mixture of amplification
primers and fluorescent dye-labelled
dideoxynucleotides (once incorporated the sequence
reaction stops),
 fragment size separation by electrophoresis in
denaturing polyacrylamide gel with simultaneous
detection and registration of products,
 Data analysis of the results using computer
programs.
During asymmetric PCR all possible oligonucleotides
of different lengths, complementary to the template and
containing fluorochromes at the 3’-end are created. They
are size separated by electrophoresis and the base order
of coloured nucleotides can be read as the sequence
complementary to the template. The detected DNA
sequence is compared with the wild type sequence
(Figure 2) available in databases such as GenBank and
EMBL, and the type of change can be precisely
described.
Currently, the major DNA sequencing companies pro-
vide modern automated DNA sequencing instruments
(DNA sequencers) that can simultaneously sequence up
to 96 samples using capillary electrophoresis. Recentmutation in MSH2 (mutS homolog 2) gene (solid line) compared
Figure 2 Chromatograms for DNA sequencing: studied sequence with c.83C>T mutation in MLH1 (mutL homolog 1) gene (upper) and
‘wild’ sequence (below).
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based not only on the increased number of simultan-
eously analysed samples but also on an improved “chem-
istry” that includes a higher resolution capillary gel
composition that has resulted in the ability to accurately
sequence almost one thousand bases of amplified DNA.
More recently commercially available next-generation
sequencing (NGS) platforms have appeared that promise
to significantly reduce DNA sequencing costs. Many
different types of instrument have been produced that
are still being perfected for diagnostic applications, such
as the Roche 454 and GS Junior system (www.454.com)
and the Illumina Genome Analyzers, HiSeq and MiSeq
(www.illumina.com), Ion Proton and Ion torrent (www.
iontorrent.com). Although these are designed mainly for
sequencing whole genomes, some of them have applica-
tions similar to traditional sequencing such as targeted
re-sequencing and mutation detection [19]. The advan-
tage of this new approach to DNA sequencing is that
selected panels of genes can be screened for germline or
somatic mutations in a single reaction [20-22]. This is
especially important for cancer predispositions, as it will
be possible, for example, to screen all genes associated
with breast cancer risk in a single reaction. An even
greater potential which would herald a total revolution
in molecular diagnostics are the new techniques aimed
at reading a sequence of native DNA without the need
for pre-amplification, termed True Single Molecule Se-
quencing (www.helicosbio.com), SMRT TECHNOLOGY(www.pacificbiosciences.com) or the GridION system
based on NanoPore technology announced by Oxford
NanoPore Technologies, based in Oxford, UK.
The 454 Genome Sequencer 20 (454 Life Sciences,
Roche Applied Sciences, Indianapolis, IN) was the first
commercially available, next-generation sequencing in-
strument, with the current 454 FLX+ system being the
recently upgraded version. These new sequencers, FLX+
machines, rely on real time sequencing by simultaneous
synthesis of many DNA fragments (around 700 hundred
base pairs in length). They apply pyrosequencing tech-
nology that detects base additions by luminescence as a
result of ATP degradation during the sequencing reac-
tion and can read up to 900 Mb at a time.
Pyrosequencing [23,24] uses a single strand of a DNA
fragment as the template on which synthesis of a com-
plementary strand is performed through the addition of
4 different deoxynucleotide triphosphates (dNTPs). The
addition of each base is associated with the liberation of
pyrophosphate which is transformed into ATP using sul-
furylase and adenosine-5’-phosphosulphate. ATP is used
by luciferase for the transformation of luciferin into
oxyluciferin. During this reaction light is generated with
an intensity proportional to the amount of pyrophos-
phate produced. The emitted light is registered by a
CCD camera and transformed into peaks on a pyrogram
(Figure 3). The same reaction scheme is used for each
dNTPs. If the added nucleotide is not complementary to
the template it is not included in the newly synthesised
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of a light signal is the requisite for adding a new nucleo-
tide to a given sequence. Based on our own experience
the major disadvantage of pyrosequencing technique is
the difficulty in determining the number of incorporated
nucleotides in homopolymer regions. In homopolymer
regions of more than 5 nucleotides, the estimation of
complementary added nucleotides is not possible due to
a nonlinear light response. However the problem can
be solved by using nucleotide reversible terminators
(NRTs), analogues modified by attaching a cleavable
fluorophore to the base and a chemically reversible moi-
ety to the 3’ cap (3’-O-allyl or 3’-O-(2-nitrobenzyl)). Dur-
ing the extension step when the complementary NRT is
incorporated, the reaction is temporarily terminated and
resumed only when the capping moiety is removed (by
de-allyation or laser irradiation). In this way, when ana-
lysing the results, each peak correspond to each incorpo-
rated nucleotide and homopolymeric regions can be
clearly identified [25].
Despite the appearance of an application to the
sequencing of genes related to hereditary cancer syn-
dromes [26,27] and significantly lower cost [28] the use
of this technology has not yet become widespread. There
are also inherent problems in NGS approaches as overall
the instrumentation is inaccurate and as such accuracy
is only achieved by repeating reactions many times such
that fold coverage must be high before statistical confi-
dence in the results can be achieved.
Southern method and MLPA (multiplex ligation-
dependent probe amplification)
A technique very popular in the past for the detection of
large rearrangements was Southern blotting, described
for the first time by E. M. Southern in 1975. Currently
this method has been almost completely replaced by
MLPA (multiplex ligation-dependent probe amplification)
[29] for the detection of large genomic rearrangements
targeting specific cancer predisposition genes. MLPA is
based on the ligation of specific probes and theirFigure 3 Pyrograms: patient with c.2932C>T in APC (adematous polypsubsequent amplification that allows an assessment of
exon copy number to be made either fore a single exon
or an entire gene. On this basis, conclusions can be
drawn concerning deletions or duplications of gene frag-
ments or whole genes.
In this technique many probes are used simultaneously
in a single reaction. Probes matching the sequences
complementary to exon sequences also contain primer
sequences and one of each of the pairs additionally con-
tains a unique insertion sequence called a stuffer se-
quence. Hybridising sequences of each pair of probes
match neighbouring DNA fragments occurs and only if
this is complete can ligation take place. After probe
hybridisation to the template, the DNA fragments are
ligated and denatured. The dissociated ligated probe
containing primer sequences is then amplified using
PCR. The presence of stuffers of different lengths allows
differentiation of the products that have labelled differ-
ent targets (in this case, exons with the gene in ques-
tion), and the amount of product is proportional to the
copy number in the template. Each peak corresponds to
the product of amplification of specific ligated pairs of
probes (Figure 4). Relative differences in the height or
area of the peak indicate quantitative (sometimes quali-
tative) changes of a target sequence for the probe. In the
event a single exon appears to be missing in the gene in
question, caution must be made as it may be due to the
presence of a polymorphism under the target sequence.
To overcome this, all single exon deletions should be
sequenced to confirm that the primer binding sites are
wild type and do not harbour a polymorphism that
would disrupt the assay integrity.
The advantages of this technique are that only a small
amount of DNA is necessary to perform analyses and
that efficiently reproducible results may be achieved
even from degraded genetic material.
Commercially available probes include those for the
most important genes associated with a high risk of
tumours, such as: ATM, BRCA1, BRCA2, CHEK1,
MLH1, MSH2, MSH6, PMS2, EPCAM, APC, FANCA,
FANCD2, PTCH, BMPR1A, SMAD4, TP53, CDH1,osis coli) gene (upper) and ‘wild’ type (below).
Figure 4 Result of MLPA electrophoresis of a sample with deletion of exon 9 in MSH2 (mutS homolog 2) gene (upper) and ‘wild’ type
(below).
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CDKN2B, WT1.
HRMA (high resolution melting analysis)
This real-time PCR based method can be used for detec-
tion of SNPs as well as for large rearrangements. All
mutations (small and large) can be screened simultan-
eously in one assay, which reduces screening time. The
basis of the genotyping is a unique pattern of melting
curves.
The first step of the analysis is real-time PCR with
fluorescent dye, mostly SYBR Green, LCGreen or Syto 9
[30]. That allows monitoring the amplification of the
DNA template, since fluorescence intensity is propor-
tional to the amount of double-strand DNA (dsDNA).
After overheating, the melting behaviour of the PCR
products is monitored by plotting the changes in fluor-
escence that occur by denaturating double-strand DNA
(dsDNA) (Figure 5). The pattern of melting temperature
(Tm) differences allows the discrimination of homo- and
heterozygotes. The main problem of HRM is that differ-
ences in the shape of melting curve can easily identifyheterozygotes, but may not distinguish all homozygotes
[31]. However, the high sensitivity and specificity, low
cost, small amount of DNA required (<5 ng) and the
simplicity of the method are prominent features that
make HRM a great candidate as a new screening method
for mutation detection for genetic cancer predispositions
[30,32].
RNA analyses
The advantages of RNA analyses are mainly due to the
possibility of detecting a mutation using a lower number
of reactions (this is related to the shorter length of RNA
in comparison to DNA). So far the main disadvantages
of these techniques have included difficulties in achiev-
ing reproducible results, lower stability of RNA with
mutations and difficulties in interpretation as a result of
the occurrence of RNA alternative splicing.
RNA analyses includes three main stages:
 RNA isolation,
 amplification of coding parts of the genes,
 detection of changes in amplification products.
Figure 5 Melting curve and melting peaks charts of a heterozygous mutation in exon 23 in NF-1 (neurofibromatosis 1) gene during
screening by HRMA.
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In the majority of laboratories, RNA is isolated from
peripheral blood lymphocytes. RNA isolation is performed
similarly to DNA isolation. However, due to the wide-
spread presence of thermostable RNAses in tissues, RNA
isolation has to be performed more carefully. It is very
popular to use the isolation method by Chomczyński [33]
from cellular lysates in a solution of guanidine thiocyanate
(RNAse inhibitors) followed by extraction in a mixture of
phenol and chloroform. The slightly acidic pH of phenol
leads to removal of not only proteins but also of DNA,
which under such conditions is practically insoluble.
RT-PCR (reverse transcriptase PCR)
RNA can be reverse-transcribed into cDNA (comple-
mentary DNA) using reverse transcriptase and then
amplified using standard PCR conditions. Since RNA
does not include introns only a few pairs of primers are
enough to amplify the entire coding region of the
selected gene. Primers should be designed to overlap
one another so that the entire gene can be analysied.
Analysing cDNA on regular agarose gels usually allowsdetection of RNA abnormalities, which are the result of
deletions or insertions of a few base pairs or splice site
mutations.
Detection of alterations in amplification products
Products of the RT-PCR reaction can be analysed using
all of the techniques described above and by using the
in vitro transcription translation (IVTT) assay, also
known as the protein truncation test (PTT) [34,35]. RT-
PCR is the first stage of PTT. For PTT one primer
includes sequence information that is used for initiating
transcription into cDNA as well as translation – to allow
in vitro protein synthesis from a cDNA template. After
translation the protein product is sized separated by
electrophoresis and transferred onto a nylon membrane.,
The length of the synthesised protein is assessed against
the theoretically expected size and any products that are
smaller (or larger) that expected will be identified. This
will include the effects of large deletions or insertions as
well as single nucleotide mutations leading to stop cod-
ing (TGA, TAA or TAG) or splicing mutations. The
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missense mutations.
Finally, it is estimated that even if we use all known
tests for the direct detection of mutations their sensitiv-
ity does not exceed ~ 70-80%, most lekiely due to a lack
in the diagnosis of changes associated with the regula-
tion of gene expression.
Detection of known mutations
There is accumulating knowledge about the type and
frequency of mutations predisposing to tumours, which
can be population specific. These include both founder
mutations and recurrent mutations in families of a given
ethnic group. DNA tests aiming to detect all known
founder mutations within a population are highly valu-
able due to an unusually high economical effectiveness.
genes such as BRCA1, MLH1, MSH2 and VHL have
been studied intensively and it is known which muta-
tions should be studied first prior to more expensive and
extensive screens [36-38] in many populations.
The most frequently applied DNA tests used for detect-
ing known mutations include the following techniques:
 restriction fragment-length polymorphism-(RFLP)
PCR
 allele-specific amplification
 real-time PCR with TaqMan probes/SimpleProbes
 matrix assisted laser desorption/ionization time of
flight
 SNaPshot genotyping
 strip assay based on primer extension reaction
RFLP-PCR (restriction fragment-length polymorphism-PCR)
Restriction enzymes identifying specific sequences of the
PCR products are described. This approach can be used
for the detection of all mutations that lead to loss or cre-
ation of restriction sites. Amplified products containing a
particular change are digested by restriction enzymes and
then size separated on agarose or polyacrylamide gels.
ASA (allele-specific amplification) – detection of
mutations using specific oligonucleotides
A conventional variant of this technique uses not only
flanking primers but also a primer fully complementary
to the allele with a mutation or a primer that is comple-
mentary to the allele with a mutation and another to the
wild allele, followed by agarose gel electrophoresis. Pri-
mers are localised in such a way that different PCR pro-
ducts are of different length depending on the genotype
of the examined DNA sample. This technique, popular
in the past, is now applied mainly in small laboratories
without specialised equipment.
The modern version of this technique uses short
allele-specific probes and real time PCR [39,40]. Thisallows very fast analysis of many DNA samples. Tech-
nology using a template with oligonucleotides immobi-
lised on a solid phase can be considered as a modern
version of ASA. A big advantage of this technology is
automation and the possibility of analysing up to a few
thousand known mutations. In many countries the use
of such technology is limited due to high costs.
Real-time PCR
One of the most modern and more frequently applied
techniques in molecular biology is real time PCR which
allows for the monitoring of the quantity of PCR pro-
ducts in each amplification cycle. A modification of this
technique based on the application of fluorescent probes
and complementary to the sequences of examined DNA
fragments can be also applied to the identification of
known genetic changes.
There are several systems based on this technique that
differ in the type of probe used for detection of the tar-
geted changes. Among them, systems applying TaqMan
and Simple probes stand out.
TaqMan probes
Each of the two probes specific to the amplified frag-
ment (to ‘normal’ and ‘mutant’ DNA variant) used in this
sys-tem is labelled at the 5’ end by reporter dye: FAM
(6-carboxy-fluorescein), VIC, HEX (hexachloro-6-carboxy-
fluores cein), TET (tetrachloro-6-carboxyfluorescein) or
JOE (2,7-dimethoxy-4,5-dichloro-6-6-carboxy-fluorescein)
and at the 3’ end by quenching dye: TAMRA (6-carboxy-
tetramethyl-rhodamine) or DABCYL (4-(4’-dimethylamino
phenylazo)benzoic acid). The short distance between dyes
within the same probe leads to quenching of the fluores
cence. During the PCR reaction at the stage of primer
annealing, a labelled probe is linked specifically to a specific
template between sites of primer hybridisation. Its 3’ end is
unavailable, which means that in the next stage – primer
extension – this probe cannot be elongated with primers.
Polymerase used in this system shows 5’-3’ activity and
degrades the probe during DNA strand building. This leads
to release of the reported dye from the quenching dye
and causes increased fluorescence of one (in case of ho-
mozygote) or two (in case of heterozygote) reporter dyes
(Figure 6). This process occurs during each cycle, causing
an increase of the fluorescence signal from each cycle,
which allows signal detection at each moment of the
reaction.
Probes used in this system are 20–40 nucleotides in
length. The number of GC pairs in their sequence is
40-60%. Probes should not include single nucleotide
repeats, particularly guanine. Also the sequence of
the probe should not be complementary to primer
sequences or to sequences of the template at the sites of
the annealing primers. It is important that the probe
Figure 6 TaqMan allelic discrimination for MLH1 (mutL homolog 1) c.677 G>T assay. The G/G genotype is shown as light triangle-shaped
dot, the G/T genotype as dark triangle-shaped dot, blank control as round-shaped dot.
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ence quenches reporter dye even after separation of it
from quenching [41]. Modification of this system can be
achieved by applying a TaqMan probe (described as a
Minor Groove Binder or MGB type), in which the group
MGB is fixed to the 3’ end. It protects stabilisation
of probe annealing by matching the complex resulting
from probe and template DNA. Interaction of the MGB
group with the probe-template complex increases the
temperature of probe melting by 15-30°C, which allows
the use of probes of much shorter sequence (14–18
nucleotides). This is valuable during analyses of single
nucleotide polymorphisms because it is easier to desta-
bilise short probes under the influence of nucleotide
changes in the examined sequence [42].
Simple probes (guanine quenching probes)
Guanine shows features of quenching fluorescence of
such molecules as FAM or JOE. In this technique a
short one-strand DNA fragment of 20–30 nucleotides in
length (molecular probe) with a sequence complemen-
tary to the examined DNA containing the change/muta-
tion labelled at 5’ or 3’ by fluorescent dye (FAM or JOE)
is used. This technique allows identification ofheterozygote and homozygote variants or mutations by
measuring the increase in fluorescence achieved in the
temperature gradient (Figure 7). The probe hybridising
with the examined sequence is usually at a higher melt-
ing temperature if it hybridises with the fully comple-
mentary strand and lower melting temperature if an
unpaired nucleotide is found in the probe. Reading the
fluorescence levels during the temperature increase in
the range 40-80°C allows the specific DNA change to be
identified. Application of complementary fluorescent
probes has several advantages. They include: high sensi-
tivity, short time and full automation of the analyses and
low risk of contamination by performing all stages in
closed wells. The disadvantages of this technique include
the necessity of protecting probes for particular sequences
and low generality of experimental conditions [41].
MALDI-TOF (matrix assisted laser desorption/ionization
time of flight)
MALDI-TOF is one of the techniques of mass spectrom-
etry, applied for detection of changes within examined
DNA fragments. Most frequently it is used for analyses
of single nucleotide polymorphisms (SNPs). Analyses are
preceded by stages based on PCR amplification. The first
Figure 7 Melting curve and melting peak charts for mutation in c.178 G>T in MC1R (melanocortin 1 receptor) gene (heterozygote)
compared with wild type (homozygote) using real-time PCR with Simple probes.
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multiplex version) containing the SNP to be examined.
The second is asymmetric (one primer complementary
to the sequence close to the polymorphic site), similarly
to sequencing with application of dideoxy-nucleotides.
After cleaning using ion exchange resin the samples are
placed on Spectrochip and finally stimulated using a
laser impulse for ion excitation. Total analysis is per-
formed under vacuum, which means that the ion mobil-
ity is not disturbed by colliding gas particles. The speed
of movement of the exited ions from the examined DNA
sample is analysed by a detector that measures the time
of ion flight. Ions from larger mass reach the detector
more slowly than ions from a smaller mass. Nucleotide
differences occurring in examined DNA samples are cor-
related with mass, which allows their differentiation
(Figure 8). Separation of analysed particles is performed
based on the ratio of ion mass to their electric charge
[43,44]. This technique is characterised by high sensitiv-
ity, rapid analysis and relatively low cost (~2 euro
to screen up to 40 mutations for one patient) [45].
Sequenom MassARRAY (www.sequenom.com) based on
MALDI-TOF allows up to 76 thousand genotypes in oneday. Only the high costs of the machine explain the low
popularity of his technique.SNaPshot genotyping
SNaPshot genotyping is a method that incorporates PCR
multiplexing. Each DNA sample under analysis is PCR-
amplified and subjected to asymmetric PCR reaction
where the primer is annealed to the target DNA directly
upstream or downstream of the mutation and then
extended with DNA polymerase by a single appropriate
fluorescent labelled dideoxynucleotide. The product
mixture is separated by polyacrylamide gel electrophor-
esis and analysed by fluorescence detection [46]. Each
released product has a specific length that identifies the
polymorphic locus and one (in case of homozygotes) or
two (in case of heterozygote) of four possible dideoxynu-
cleotides labelled by a specific fluorescence dye that
matches the nucleotide at the target site. Visualisation
and analysis of the DNA fragments is accomplished by
DNA sequencer [47].
According to literature several genetic loci can be sim-
ultaneously amplified in a single reaction tube [46-48].
Figure 8 Mass spectrum of a sample with c.3959_3962delCAAG mutation in MSH6 (mutS homolog 6) gene. Each peak corresponds with
each DNA variant.
Kurzawski et al. Hereditary Cancer in Clinical Practice 2012, 10:17 Page 11 of 13
http://www.hccpjournal.com/content/10/1/17With the capability of high multiplexing, this genotyping
method stands out as a robust approach for analysis of
known point mutations.
Strip assay based on primer extension reaction
Dry-reagent strip assay is a novel method, characterised
as fast, inexpensive and easy, which enables a visual de-
tection of DNA variants without specialised equipment.
Therefore it is a great alternative for small laboratories.
Allele discrimination is based on hybridisation of
mutant-allele and normal-allele specific products on the
nitrocellulose strip [49,50].
Analysis consists of two PCR reactions: DNA amplifi
cation and primer extension reaction employing allele-
specific primers, dATP, dCTP, dGTP and digoxygenin-
and biotin-dUTP (for each allele – ‘normal’ and
‘mutant’) instead of dUTP. Primer extension reaction
products are applied to the strip with immobilised anti-
digoxigenin and streptavidin, and migrate along by capil-
lary action. Because of the use of gold nanoparticles
as reporters, the presence of DNA variants is identified
as (one - in case of homozygote -, or two - in case of
heterozygote) coloured red spots [49].
The strip assay has proven its diagnostic value as an
effective and sensitive method [49,51]. It enables rapid
mutation assignment. After PCR amplification visualisa-
tion of primer extension reaction products is completed
in about 15 minutes. A great advantage is that, as
opposed to most genotyping methods, it does not re-
quire costly specialised instrument [49]. The only prob-
lem could be non-specific binding and misclassifying
homo- and heterozygotes but this can be avoided by test
optimisation [51]. Nevertheless, strip assay seems to be a
noteworthy mutation detection method.COLD-PCR
Co-amplification at lower denaturation temperature PCR
(COLD-PCR) is a novel modification of the conventional
PCR method that selectively amplifies minority alleles from
a mixture of wild type and mutant sequences irrespective
of the mutation type or position within the sequence [52].
This method is based on the observation that there is a
critical denaturation temperature (Tc) for each DNA
sequence, which is lower than its melting temperature
(Tm). PCR amplification efficiency for a DNA sequence
drops abruptly if the denaturation temperature is set below
its Tc.
There are two forms of COLD-PCR that have been
developed to date: full COLD-PCR and fast COLD-PCR.
Full COLD-PCR includes five stages that are used for
each round of amplification:
1. Denaturation – denaturation of the template DNA
2. Intermediate annealing – heteroduplexes formation
3. Melting – melting of heteroduplexes at Tc
4. Primer annealing – annealing of primers to single
stranded heteroduplex DNA, homo duplex DNA
remain double stranded and is not available for
primer annealing
5. Extension – extension of the template DNA by DNA
polymerase
In Fast COLD-PCR the denaturation and intermediate
annealing stages are skipped.
COLD-PCR is a sensitive platform for the detection of
low-abundance mutations and can be used to improve
the reliability of a number of different assays that trad-
itionally use conventional PCR, eg. RFLP, sequencing,
MALDI-TOF, and real time PCR. Replacing traditional
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increases the reliability in detecting mutations from
mixed samples, including tumors and body fluids.
Summary
Liquid handling robots have been applied to DNA or
RNA isolation, normalisation of sample concentration,
PCR preparation, and a variety of other more tedious
aspects of mutation detection. The parallel development
of software and hardware has enabled complete auto-
matic management of large sample series in genetic
testing, including data transfer without any user inter-
vention. Nowadays leading companies offer capillary
sequencers capable of analysing simultaneously up to 96
samples amplified by means of cycling sequencing with
fluorescent dyes. Improved “chemistry” and capillary gel
composition has enabled accurate sequencing of frag-
ments up to 1000 bp in length. Another system Illumina
HiSeq 2000-v3 based on massive parallel sequencing by
cyclic technology, can generate 600 000 Mb in a single
run. Real-time PCR techniques with TaqMan probes
have become commonly used in laboratory practice.
MLPA technique used in detection of rearrangements in
genes associated with hereditary cancers allows the
determination of exon copy number. The presence of
deletions or duplications of exons or whole genes can be
analysed by that method or by the HRMA technique,
which also allows simultaneous point mutation detec-
tion. Methods like MALDI-TOF or SNaPshot genotyp-
ing with the capability of multiplexing enable more
cost-effective and less time-consuming testing.
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